Back

Real-world insights into treatment modalities and emerging myosin inhibitor therapy for hypertrophic obstructive cardiomyopathy: early findings from the German REDUCE-Registry

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Left ventricular outflow tract obstruction Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Leni Katharina Seuthe

Cologne University Hospital - Heart Center, Cologne (Germany)

6 More presentations in this session

Presentation thumbnail
Multicenter study on the effect of Mavacamten on pulmonary artery systolic pressure derived from echo-doppler in obstructive hypertrophic cardiomyopathy
Doctor M. Gegenava (Tbilisi, GE)
Abstract Slides Video
Presentation thumbnail
Comparison of characteristics and outcomes of patients with obstructive vs. non-obstructive hypertrophic cardiomyopathy in a cohort from a referral center in colombia
Doctor J. Orozco Burbano (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Outcomes of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in Japan
Doctor T. Yamaguchi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Genetic, echocardiographic and clinical determinants of mitral valve abnormalities in hypertrophic cardiomyopathy
Miss H. Panholzer (Graz, AT)
Abstract Slides Video
Presentation thumbnail
Common pathophysiological mechanism of SAM and mitral regurgitation in HOCM
Associate Professor Z. Wang (Hangzhou, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Left ventricular outflow tract obstruction

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Evaluation of clinical need, effectiveness, and safety of the first myosin inhibitor mavacamten in real world patients
thumbnail
Congress Presentation
Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources